Vesilute: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 6 sources cited

Overview

Vesilute is a synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson bioregulator family. Its developers list it as a bladder (genitourinary) regulator. The vascular peptide of this family is Vesugen (Lys-Glu-Asp), a different compound. No experimental study of Vesilute in cells, animals or people has been published.

Mechanism of Action

Like other Khavinson bioregulators, Vesilute is proposed to interact with DNA regulatory regions and modulate gene expression in its target tissue, which its developers give as the bladder. No published experiment has tested this for the Glu-Asp dipeptide. The only published data are computer docking results predicting that it binds the amino acid and peptide transporters LAT1, LAT2 and PEPT1, which could carry it into cells. Effects on eNOS, nitric oxide production or adhesion molecules (ICAM-1, VCAM-1) have not been published for Vesilute.

Vesilute Benefits: What the Research Shows

  • Khavinson peptide research demonstrates that short peptides (2–4 amino acids) can penetrate cell nuclei and interact with gene regulatory regions
  • Studies on vascular bioregulators, such as improved arterial blood flow in 41 men treated with the tripeptide Vesugen, concern a different peptide; no study of Vesilute in people has been published
  • Computer docking predicts that the Glu-Asp dipeptide binds the LAT1, LAT2 and PEPT1 transporters; this is the only published data on Vesilute's sequence

Vesilute Dosage

  • Standard bioregulator protocol: 1–2 capsules (10–20 mg) daily for 10–30 days
  • Injectable (if available): 10 mcg subcutaneously every other day for 10–20 days
  • Repeat courses every 3–6 months
  • Take on an empty stomach for optimal absorption
  • No cycling requirement but periodic breaks between courses are standard practice
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Vesilute Side Effects & Safety

Known Side Effects

  • No human or animal studies of Vesilute have been published, so side effects have not been assessed
  • Developers describe bioregulator peptides as well tolerated, but Vesilute has no published tolerability data
  • Cardiovascular and other adverse events have not been studied
  • Theoretical concern about altering gene expression in unintended cell types

Safety Profile

Vesilute has no published safety data of any kind: no human, animal or cell study of the Glu-Asp dipeptide was found, only computer modeling. Its developers describe short peptides as well tolerated, but this has not been tested for Vesilute. The compound is not FDA-approved or regulated as a pharmaceutical in most Western countries. No known contraindications or drug interactions are established. Its efficacy claims have no published evidence, independent or otherwise.

What to Expect

Bioregulator effects are described as subtle and gradual. Week 1–2: No noticeable effects. Week 2 onward: The improvements in circulation, warmth in extremities and vascular function sometimes listed for Vesilute describe the vascular peptide Vesugen, not Vesilute. No published study has measured any effect of Vesilute in people, on the bladder or elsewhere, and repeated courses have not been studied.

Storage & Handling

Store capsules at room temperature (15–25°C), protected from moisture and light. Shelf life: 2–3 years. Injectable form: store lyophilized powder at 2–8°C; reconstituted solution at 2–8°C for up to 14 days.

Pricing & Available Variants

$60price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track Vesilute in Your Protocol

Log your Vesilute doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free